QUIDEL CORPORATION (NASDAQ:QDEL) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition.
In connection with Quidel Corporation’s participation at the 37th Annual J.P. Morgan Healthcare Conference to be held on Wednesday, January 9, 2019, the company is providing preliminary unaudited revenue results for its fourth quarter of 2018. Based on preliminary financial information, Quidel expects revenues in the fourth quarter of 2018 to be between $132 million and $133 million.
These preliminary results are based on management’s initial analysis of operations for the quarter ended December 31, 2018. The company expects to issue full financial results for the fourth quarter and fiscal year 2018 in February.
The Company issued a press release announcing its preliminary revenue results for the quarter ended December 31, 2018 on January 7, 2019. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K.
Forward Looking Statements: The financial information set forth in this Form 8-K reflects the company’s current preliminary revenue estimates, is subject to the completion of its audit process, and is subject to change. The company’s full fourth quarter and year 2018 results could differ materially from the preliminary estimates provided in this Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date of this Form 8-K. We undertake no obligation to publicly release the results of any revision or update of the forward-looking statements, except as required by law.
Item 7.01Regulation FD Disclosure.
As referenced above, in connection with the company’s participation at the 37th Annual J.P. Morgan Healthcare Conference to be held on January 9, 2019, the company is reporting cumulative worldwide Sofia instrument placements of over 35,000 at customer sites as of December 31, 2018.
Item 9.01Financial Statements and Exhibits.
QUIDEL CORP /DE/ Exhibit
EX-99.1 2 ex-991qdelq42018prexannoun.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 Quidel Contact: Media and Investors Contact:Quidel Corporation Quidel CorporationRandy Steward Ruben ArguetaChief Financial Officer 858.646.8023858.552.7931 [email protected] QUIDEL ANNOUNCES PRELIMINARY REVENUE FOR FOURTH QUARTER 2018SAN DIEGO–(BUSINESS WIRE)-Jan 7,…
To view the full exhibit click here
About QUIDEL CORPORATION (NASDAQ:QDEL)
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The Company’s diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. It markets its products in the United States through a network of national and regional distributors and a direct sales force. Internationally, it sells and markets primarily through distributor arrangements. Its diagnostic solutions are used in the detection and diagnosis of many critical diseases and other medical conditions, including autoimmune diseases, bone health and thyroid diseases. It provides diagnostic testing solutions under various brand names, including Quidel, QuickVue+ and Thyretain.
